Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects

Elevated lipoprotein (a) [Lp(a)] levels increase the risk for CVD. Novel treatments that decrease LDL cholesterol (LDL-C) have also shown promise for reducing Lp(a) levels. Mipomersen, an antisense oligonucleotide that inhibits apoB synthesis, is approved for the treatment of homozygous familial hyp...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Lipid Res
Egile Nagusiak: Nandakumar, Renu, Matveyenko, Anastasiya, Thomas, Tiffany, Pavlyha, Marianna, Ngai, Colleen, Holleran, Stephen, Ramakrishnan, Rajasekhar, Ginsberg, Henry N., Karmally, Wahida, Marcovina, Santica M., Reyes-Soffer, Gissette
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The American Society for Biochemistry and Molecular Biology 2018
Gaiak:
Patient-Oriented and Epidemiological Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6277161/
https://ncbi.nlm.nih.gov/pubmed/30293969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.P082834
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak